GI
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma
FEATURING
Sheela Rao
- 5 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study
FEATURING
David Tougeron
- 3 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro + CAPOX + Bevacizumab in MSS mCRC With High Immune Infiltrate - FFCD 1703 POCHI Trial
FEATURING
David Tougeron
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Treatment Strategies and Sequencing in Carcinoid Syndrome
FEATURING
Rachel Riechelmann
- 47 views
- September 24, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose
FEATURING
Howard Hochster
- 97 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC
FEATURING
Lorenza Rimassa
- 140 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - Ph3 LEAP-012 Study
FEATURING
Josep Llovet
- 59 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC
FEATURING
Lorenza Rimassa
- 93 views
- September 20, 2024